Rituximab

Rituximab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma、Leukemia, Lymphocytic, Chronic, B-Cell、Leukemia, Chronic Lymphocytic、Small-Cell Lymphoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Rituximab 研究

• DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)

  I 期 / II 期招募中中国NCT07059650

• A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis

  III 期招募中法国NCT07189325

• Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma

  II 期招募中美国NCT07583810

• Pembrolizumab, Ibrutinib and Rituximab in PCNSL

  I 期 / II 期招募中美国NCT04421560

• RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL

  II 期招募中中国NCT06674096

• Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia

  不适用招募中意大利NCT05931718

• BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma

  II 期招募中美国NCT06854003

• Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL

  I 期 / II 期招募中中国NCT06760039

• IGNITE: Study of Tirabrutinib vs Rituximab and Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

  III 期招募中美国澳大利亚BrazilCzechiaNCT07104032

• Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma

  I 期 / II 期招募中中国NCT06829771

• A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

  I 期 / II 期招募中美国澳大利亚Brazil中国NCT05533775

• Epco, Zanu, Ritux for R/R FL or MZL

  II 期招募中美国NCT06563596

• Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement

  I 期 / II 期招募中中国NCT04432714

• The Efficacy and Safety of Desensitation Regimen for Patients With High Titers of Anti-HLA Antibodies Prior to Allo-HSCT

  II 期招募中中国NCT06362967

• The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk

  III 期招募中中国NCT05018520

• Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

  II 期招募中美国NCT06263491

• Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

  II 期招募中奥地利比利时CroatiaCzechiaNCT04844866

• CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

  I 期招募中美国NCT06209619

• A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

  III 期招募中美国澳大利亚Brazil加拿大NCT06084936

• Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma

  II 期招募中美国NCT07731789

• A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma

  I 期 / II 期招募中中国NCT06683885

• Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

  II 期招募中美国NCT03418038

• A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

  II 期 / III 期招募中美国Argentina澳大利亚ChileNCT07634471

• A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients

  II 期招募中中国NCT06569485

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。